Subcutaneous epcoritamab in R/R B-cell NHL

(2:42)

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL

(1:49)

Subcutaneous Epcoritamab for Richter's Syndrome - Dr. Arnon Kater ASH 2022

(12:37)

Early results from EPCORE CLL-1 trial: subcutaneous epcoritamab in patients with Richter’s syndrome

(1:9)

Subcutaneous epcoritamab in R/R B-cell non-Hodgkin lymphoma

(9:41)

EPCORE NHL-1: health-related QoL in patients with R/R LBCL treated with subcutaneous epcoritamab

(1:18)

Follicular Lymphoma 360: The Latest Treatment Options For Me | The Patient Story

(1:11:31)

How the Latest Non-Hodgkin Lymphoma Treatments SAVED MY LIFE | What You NEED TO KNOW

(34:1econd)

Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma | LRF Webinars

(1:40)

Update on Bispecific Antibodies | Lymphoma Research Foundation Webinars

(1:1:25)

How to Treat Follicular \u0026 Mantle Cell Lymphomas - Discussion with Dr. Pallawi Torka

(26:17)

DLBCL Treatment Approaches: What You Need to Know

(29:38)

ASH 2024 Comes to You!

(1:30:50)

Lymphoma Focus Day High grade non Hodgkin lymphoma Dr Adam Gibb

(43:16)

How to Give Subcutaneous Fluids to Your Cat at Home

(8:13)

Update on Lymphoma from the 2022 American Society of Hematology ASH Annual Meeting | LRF Webinars

(1:1:18)

Phase II study of epcoritamab in R/R LBCL

(1:38)

Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD

(5:36)

EPCORE NHL-2: epcoritamab with rituximab and lenalidomide in newly diagnosed and R/R FL

(7:45)

Exploring the Approval of Epcoritamab for Diffuse Large B-Cell Lymphoma With Reid Merryman, MD

(5:57)

Genmab and AbbVie Present New Epcoritamab Data at EHA 2023

(8:)

An update on the EPCORE NHL-1 trial

(1:35)

Epcoritamab + R-Mini-CHOP in previously untreated DLBCL: insights from EPCORE NHL-2

(2:24)

Results of Phase I/II study of epcoritamab+R-DHAX/C in patients with R/R DLBCL eligible for autoSCT

(2:42)

Epcoritamab a Bispecific Antibody to Treat CLL (Chronic Lymphocytic Leukemia)

(7:56)

How to use Epcoritamab-Bysp 4 Mg/0.8 Ml Subcutaneous Solution (Must Dilute) - Explain Uses,Side Eff

(7:40)

Epkinly Clinical Pearl

(8:41)

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab \u0026 more

(2:8)

New DLBCL Clinical Trial: Epcoritamab for Diffuse Large B-Cell Lymphoma

(1:9)

The role of epcoritamab in third-line or later LBCL

(3:9)